MedTrace Logo

Continuous Theta Burst Stimulation for Generalized Anxiety Disorder

NCT07770919 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-18

No results posted yet for this study

Summary

This randomized clinical trial evaluates the effectiveness of continuous theta burst stimulation (cTBS) combined with background pharmacotherapy in patients with generalized anxiety disorder. Participants will be randomly assigned to receive cTBS targeting either the right posterior parietal cortex or the right dorsolateral prefrontal cortex. The study will compare changes in anxiety symptoms between the two treatment strategies and will also assess quality of life, sleep, cognitive function, electroencephalographic measures, and transcranial magnetic stimulation-electroencephalography measures.

Conditions

Interventions

DEVICE

Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex

Continuous theta burst stimulation (cTBS) is delivered to the right posterior parietal cortex (R-PPC) at 80% of the active motor threshold (AMT). Participants receive 10 treatment sessions over approximately 1 week, in addition to stable background pharmacotherapy.

DEVICE

Continuous Theta Burst Stimulation of the Right Dorsolateral Prefrontal Cortex

Continuous theta burst stimulation (cTBS) is delivered to the right dorsolateral prefrontal cortex (R-DLPFC) at 80% of the active motor threshold (AMT). Participants receive 20 treatment sessions over approximately 4 weeks, in addition to stable background pharmacotherapy.

Sponsors & Collaborators

  • Military Hospital 175

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07770919 on ClinicalTrials.gov